View Cart  

Pharmacyclics Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial

Pharmacyclics announced the international, randomized Phase III clinical trial of ibrutinib (PCI-32765) in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma has enrolled its fifth patient.
The Sacramento Bee